Topic:

M&A

Latest Headlines

Latest Headlines

Actavis working to add Allergan CEO Pyott to board: Reuters

Back in November, Actavis said it would invite two members of Allergan's board to join the ranks of the new company's directors in the wake of their $66 billion merger. And according to Reuters ' sources, Allergan CEO David Pyott is one of them.

Glaxo CEO: Consumer health IPO may be in our future

When GlaxoSmithKline's multibillion-dollar asset swap with Novartis closes this year, don't expect the British pharma giant to stop there, its CEO says--especially when it comes to consumer health.

Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue

Earlier this week, once-skeptical Johnson & Johnson CEO Alex Gorsky seemed to be fully on-board pharma's slim-down bandwagon, telling presentation-watchers at the JP Morgan Healthcare Conference he was willing to jettison pieces of the J&J puzzle if they didn't present a "path to achieving leadership." Now, he's followed up with another divestment that will send U.S. rights to pain med Nucynta to California's Depomed.

Medical device, diagnostic venture investment at $2.7B, highest since 2008

Med tech venture investing may lag biotech by more than half, but it's coming on strong. As venture-backed exits pick up, a real devotion to breakthrough innovation seems to be whetting investor appetites. A total of $2.7 billion was invested by VCs last year in medical devices and diagnostics, with $748 million of that total coming during the fourth quarter.

Roche bets $545M on Trophos' once-failed orphan drug

Roche has signed a deal to trade up to €470 million ($545 million) for Trophos, a company at work on a mid-stage treatment for the rare and debilitating spinal muscular atrophy.

With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics

Sounds like Impax Laboratories' October pickup of Lineage Therapeutics and Tower Holdings was just the beginning of an M&A streak. The company is "aggressively hunting" further buyouts and is in ongoing talks with multiple targets, its CEO says.

The 2015 biotech takeover target list includes some hot new players

With the big multinationals like Merck, Roche, Pfizer and J&J joining some of the most aggressive biotechs (think Shire) in roaming the planet in search of the right biotech targets to acquire, you can expect to see a steady stream of fresh speculation among analysts over which companies figure as the most likely buyout--and the next place to score some quick cash by investors.

Tobira eyes Wall Street with Regado merger, targeting NASH

Tobira Therapeutics, moving on from a failed IPO of its own, is plotting a merger with the struggling Regado Biosciences, a deal that would get it on the public market as it develops a treatment for liver disease.

Shire's deal for NPS hasn't curbed its M&A appetite

Shire's M&A wheelhouse is still churning after its $5.2 billion buyout of NPS Pharmaceuticals. CEO Flemming Ornskov told Bloomberg that the Dublin-based company's recent acquisition won't prevent it from making more deals in the future--especially where rare disease drugs are concerned.

Is once-skeptical J&J coming around on pharma's breakup craze?

SAN FRANCISCO-- Johnson & Johnson has been pretty quiet over the past couple of years as it's watched its Big Pharma peers slim down like there's no tomorrow. But now, it seems the pharma giant may be coming around to the idea--or so CEO Alex Gorsky said Monday at the JP Morgan Healthcare Conference.